Preeclampsia €“ Will Orphan Drug Status Facilitate Innovative Biological Therapies?

Frontiers in Surgery - Switzerland
doi 10.3389/fsurg.2015.00007
Full Text
Abstract

Available in full text

Categories
Surgery
Date
Authors
Publisher

Frontiers Media SA

Related search

The Current Status of Orphan Drug Development in Europe and the US

Intractable and Rare Diseases Research
Medicine
2014English

Orphan Therapies: Making Best Use of Postmarket Data

Journal of General Internal Medicine
Internal Medicine
2014English

Improved Ocular Tissue Models and Eye-On-A-Chip Technologies Will Facilitate Ophthalmic Drug Development

Journal of Ocular Pharmacology and Therapeutics
OphthalmologyPharmacology
2020English

Dermatomyositis: A Slow Path Towards Targeted Therapies or Will Conventional Therapies Prevail?

British Journal of Dermatology
DermatologyMedicine
2018English

Biological Therapies for Eating Disorders

2013English

Biological Therapies for Atrial Fibrillation

Journal of Cardiovascular Pharmacology
Cardiovascular MedicinePharmacologyCardiology
2016English

Retracted: Innovative Therapies Against Human Glioblastoma Multiforme

International Scholarly Research Notices
2019English

Php345 - Innovative Payment Models for Breakthrough Therapies

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology
MedicinePharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy